GLP-1 and GLP-2 receptor co-agonist
Dapigl sc
DAPIGL_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.17 (0.09 to 86.92) | 0.41 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.67 (0.70 to 4.53) | 0.72 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.05 (0.19 to 6.94) | 0.83 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.07 (0.57 to 9.45) | 0.46 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.08 (0.77 to 17.91) | 0.34 |